^
    1d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=71, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    1d
    Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P=N/A, N=100, Not yet recruiting, Zhongnan Hospital
    New trial
    |
    PD-L1 IHC 22C3 pharmDx
    2d
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    5d
    A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=150, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • carboplatin • gemcitabine • Tyvyt (sintilimab) • pemetrexed • uliledlimab (TJD5)
    5d
    A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=450, Active, not recruiting, TJ Biopharma Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    6d
    Efficacy and Safety of Becotatug Vedotin (EGFR ADC) plus Pucotenlimab and Cisplatin as Neoadjuvant Therapy for LA-HNSCC (ChiCTR2600115972)
    P=N/A, N=30, Not yet recruiting, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin) • becotarug (JMT101)
    6d
    Sacituzumab tirumotecan plus Immune Checkpoint Inhibitor as Neoadjuvant Therapy for Resectable Stage IIIA–IIIB (N2) Non-small-cell Lung Cancer: A Single-arm, Single-center, Phase II Trial (ChiCTR2600116542)
    P2, N=34, Not yet recruiting, The General Hospital of the Eastern Theater Command of the People's Liberation Army of China; The General Hospital of the Eastern Theater Command of t
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • EGFR negative
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Loqtorzi (toripalimab-tpzi) • Jiataile (sacituzumab tirumotecan)
    6d
    Neoadjuvant immunotherapy with or without chemotherapy and minimally invasive esophagectomy in elderly patients for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, multicenter phase II clinical study (ChiCTR2500111929)
    P2, N=62, Recruiting, Shanghai Geriatric Medical Center; Shanghai Geriatric Medical Center
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    cisplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    7d
    Tumor Location Significantly Correlates With PD-L1 Status in Patients With Small Sized Non-small Cell Lung Cancer. (PubMed, Anticancer Res)
    PD-L1 expression status significantly correlated with CTR, histological type and tumor location. This is the first report demonstrating a significant correlation between PD-L1 expression and tumor location in NSCLC. We believe that differences in the cancer microenvironment based on tumor location influence PD-L1 expression status in cancer cells.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx
    14d
    Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (clinicaltrials.gov)
    P3, N=1210, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • pemetrexed
    15d
    META-1: Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels (clinicaltrials.gov)
    P2, N=275, Not yet recruiting, UNICANCER
    New P2 trial • IO Companion diagnostic • PD(L)-1 companion diagnostic
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc)
    16d
    G360-IIT: Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (clinicaltrials.gov)
    P2, N=108, Recruiting, Hackensack Meridian Health | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • Guardant360® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed